The identification of mild fetal ventriculomegaly prompts further evaluation
focused on determining whether additional structural anomalies, genetic
abnormalities or congenital infections are present. The aim of this study is
to evaluate the frequency of chromosomal aberrations in fetuses with
isolated mild symmetrical ventriculomegaly and determine the risk for a
fetus with isolated mild ventriculomegaly to have chromosomal abnormality in
a back ground. Additionally, we have performed an evaluation of the
chromosomal microarray findings in a series of five fetuses with isolated
mild symmetrical ventriculomegaly and a normal karyotype. The retrospective
observational study included karyotype evaluation of 102 fetuses with
isolated mild symmetrical ventriculomegaly identified at the time of the
routine midpregnancy scanning. In five cases array-CGH was performed and the
obtained data were compared with the data in the bioinformatics databases.
Among fetuses with isolated mild symmetrical ventriculomegaly chromosome
aberrations were found in 2 (1,96%) fetuses. In both cases autosomal
aneuploidy was detected, and those are trisomy 21 and trisomy 18,
respectively. The finding of a mild symmetrical isolated ventriculomegaly on
the routine ultrasound fetal exam in the second trimester had low
sensitivity, but high specificity and negative predictive value in the
prediction of chromosome anomalies. Copy number variants
(microduplications/microdeletions) were detected in four cases (80%). A
search for the similar variants in NCBI ClinVar, DECIPHER, OMIM and ENSEMBL
data bases, revealed that the microdeletions/microduplications detected in
four fetuses in our study cannot be related with ventriculomegaly
development. Our findings suggest that karyotyping is not justified in
fetuses with isolated mild symmetrical ventriculomegaly (10-15 mm), in a low
risk population. Therefore, when mild fetal ventriculomegaly is found in a
low risk population, additional non-invasive procedures for chromosome
aberration screening (such as noninvasive prenatal screening based on
cell-free fetal DNA) are recommended, before making the decision to perform
invasive diagnostic procedures.